Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 150

1.

Clinicopathologic features of ductal carcinoma in situ in young women with an emphasis on molecular subtype.

VandenBussche CJ, Elwood H, Cimino-Mathews A, Bittar Z, Illei PB, Warzecha HN.

Hum Pathol. 2013 Nov;44(11):2487-93. doi: 10.1016/j.humpath.2013.06.007. Epub 2013 Sep 10.

PMID:
24029706
2.

Expression of HER2neu in ductal carcinoma in situ is associated with local recurrence.

Han K, Nofech-Mozes S, Narod S, Hanna W, Vesprini D, Saskin R, Taylor C, Kong I, Paszat L, Rakovitch E.

Clin Oncol (R Coll Radiol). 2012 Apr;24(3):183-9. doi: 10.1016/j.clon.2011.09.008. Epub 2011 Sep 29.

PMID:
21958729
4.

Molecular subtypes of ductal carcinoma in situ in African American and Caucasian American women: distribution and correlation with pathological features and outcome.

Sharaf Aldeen B, Feng J, Wu Y, Nassar Warzecha H.

Cancer Epidemiol. 2013 Aug;37(4):474-8. doi: 10.1016/j.canep.2013.03.018. Epub 2013 Apr 30.

PMID:
23639792
5.

HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ.

Rakovitch E, Nofech-Mozes S, Hanna W, Narod S, Thiruchelvam D, Saskin R, Spayne J, Taylor C, Paszat L.

Br J Cancer. 2012 Mar 13;106(6):1160-5. doi: 10.1038/bjc.2012.41. Epub 2012 Feb 23.

6.

The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: a study of a large cohort of patients treated with surgery alone.

Cornfield DB, Palazzo JP, Schwartz GF, Goonewardene SA, Kovatich AJ, Chervoneva I, Hyslop T, Schwarting R.

Cancer. 2004 Jun 1;100(11):2317-27.

7.

Identification of a basal-like subtype of breast ductal carcinoma in situ.

Livasy CA, Perou CM, Karaca G, Cowan DW, Maia D, Jackson S, Tse CK, Nyante S, Millikan RC.

Hum Pathol. 2007 Feb;38(2):197-204.

PMID:
17234468
8.

Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis.

Kerlikowske K, Molinaro AM, Gauthier ML, Berman HK, Waldman F, Bennington J, Sanchez H, Jimenez C, Stewart K, Chew K, Ljung BM, Tlsty TD.

J Natl Cancer Inst. 2010 May 5;102(9):627-37. doi: 10.1093/jnci/djq101. Epub 2010 Apr 28. Erratum in: J Natl Cancer Inst. 2010 Jul 7;102(13):993.

9.

Long-term survival of women with basal-like ductal carcinoma in situ of the breast: a population-based cohort study.

Zhou W, Jirström K, Johansson C, Amini RM, Blomqvist C, Agbaje O, Wärnberg F.

BMC Cancer. 2010 Nov 30;10:653. doi: 10.1186/1471-2407-10-653.

10.

Molecular subtypes in ductal carcinoma in situ of the breast and their relation to prognosis: a population-based cohort study.

Zhou W, Jirström K, Amini RM, Fjällskog ML, Sollie T, Lindman H, Sørlie T, Blomqvist C, Wärnberg F.

BMC Cancer. 2013 Oct 30;13:512. doi: 10.1186/1471-2407-13-512.

11.

Immunohistochemical profile of high-grade ductal carcinoma in situ of the breast.

Perez AA, Rocha RM, Balabram D, Souza Áda S, Gobbi H.

Clinics (Sao Paulo). 2013 May;68(5):674-8. doi: 10.6061/clinics/2013(05)15.

12.

Male breast cancer: immunohistochemical subtypes and clinical outcome characterization.

Sánchez-Muñoz A, Román-Jobacho A, Pérez-Villa L, Sánchez-Rovira P, Miramón J, Pérez D, Sáez MI, de Luque V, Medina L, Ramírez-Tortosa CL, Vicioso L, Medina JA, Ribelles N, Alba E.

Oncology. 2012;83(4):228-33. doi: 10.1159/000341537. Epub 2012 Aug 16.

PMID:
22907070
13.

Inference of the Basal epithelial phenotype in breast carcinoma from differential marker expression, using tissue microarrays in triple negative breast cancer and women younger than 35.

Nassar A, Sussman ZM, Lawson D, Cohen C.

Breast J. 2012 Sep;18(5):399-405. doi: 10.1111/j.1524-4741.2012.01279.x. Epub 2012 Aug 10.

PMID:
22882580
14.

Young age is associated with ipsilateral breast tumor recurrence after breast conserving surgery and radiation therapy in patients with HER2-positive/ER-negative subtype.

Kim HJ, Han W, Yi OV, Shin HC, Ahn SK, Koh BS, Moon HG, You JH, Son BH, Ahn SH, Noh DY.

Breast Cancer Res Treat. 2011 Nov;130(2):499-505. doi: 10.1007/s10549-011-1736-3. Epub 2011 Aug 19.

PMID:
21853352
15.

Is there a low-grade precursor pathway in breast cancer?

King TA, Sakr RA, Muhsen S, Andrade VP, Giri D, Van Zee KJ, Morrow M.

Ann Surg Oncol. 2012 Apr;19(4):1115-21. doi: 10.1245/s10434-011-2053-0. Epub 2011 Sep 21.

PMID:
21935747
17.
18.

[Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].

Zhang HM, Zhang BN, Xuan LX, Zhao P.

Zhonghua Zhong Liu Za Zhi. 2009 Jun;31(6):447-51. Chinese.

PMID:
19950556
19.

Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ.

Curigliano G, Disalvatore D, Esposito A, Pruneri G, Lazzeroni M, Guerrieri-Gonzaga A, Luini A, Orecchia R, Goldhirsch A, Rotmensz N, Bonanni B, Viale G.

Ann Oncol. 2015 Apr;26(4):682-7. doi: 10.1093/annonc/mdv013. Epub 2015 Jan 18.

PMID:
25600567
20.

Cell biological factors in ductal carcinoma in situ (DCIS) of the breast-relationship to ipsilateral local recurrence and histopathological characteristics.

Ringberg A, Anagnostaki L, Anderson H, Idvall I, Fernö M; South Sweden Breast Cancer Group..

Eur J Cancer. 2001 Aug;37(12):1514-22.

PMID:
11506959

Supplemental Content

Support Center